Loading
RareCyte
RareCyte, in Seattle, makes two kinds of laboratory instruments: one that finds the rare tumour cells circulating in a blood sample, and one that stains a tumour slice for many proteins at once so researchers can map the cells in it.
Also called: RareCyte, Inc.
Overview
RareCyte develops spatial biology and liquid biopsy technologies. Its CyteFinder platform, designed for monitoring circulating tumour cells in clinical trials, can in the company's words phenotype as few as one CTC per tube of blood; in 2021 it announced a synaptophysin CTC assay for characterising treatment-resistant cancers from blood. Its Orion spatial proteomics platform images many protein markers on one tissue section, and in April 2026 it launched Orion HT, for clinical-scale high-plex biomarker programmes with 30-slide automation, and Orion LE, for panel development and translational studies, and named Neil Kennedy president. In June 2024 it raised USD 20 million from new and existing investors, co-led by Arboretum Ventures and F-Prime Capital, with Forest Road, HealthQuest Capital, 5AM Ventures, Agilent Technologies, founder Ron Seubert, Sheatree Capital and GKCC LLC.
Headquarters
Seattle, WA, US
Funding
All startupsGrowth stage
Investors
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| Financing · Co-led by Arboretum Ventures and F-Prime Capital; round type not named | 2024 | $20M | rarecyte.com |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Type
Stage
Growth stage
Website
Notes
- Founding year not stated on the company pages read. Headquarters is the Seattle dateline of its releases, which also refer to its Seattle laboratories. Stage growth reflects a private company with products on sale and a 2024 financing. No regulatory clearance is claimed on the pages read.
Connected
7Similar pages
- CompanyCNSide Diagnostics
Shares Circulating tumour cell capture, Liquid biopsy (ctDNA).
- CompanyRGCC International
Shares Circulating tumour cell capture, Liquid biopsy (ctDNA).
- CompanyIonpath
Shares Spatial biology instruments, Single-cell & spatial profiling.
- CompanyMenarini Silicon Biosystems
Shares Circulating tumour cell capture, Single-cell & spatial profiling, Liquid biopsy (ctDNA).
- CompanyScreenCell
Shares Circulating tumour cell capture, Liquid biopsy (ctDNA).
- CompanyANGLE plc
Shares Circulating tumour cell capture, Liquid biopsy (ctDNA).
- CompanyAdela
Shares F-Prime Capital, Liquid biopsy (ctDNA).
- PersonTrevor J. Pugh
Shares Single-cell & spatial profiling, Liquid biopsy (ctDNA).
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/